Related Experiment Video
Updated: Jun 14, 2026
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
Published on: November 6, 2019
Reversibility of functional deficits in experimental models of Rett syndrome
Stuart Cobb1, Jacky Guy, Adrian Bird
1Neuroscience and Molecular Pharmacology, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK. s.cobb@bio.gla.ac.uk
Abstract:
Mutations in the X-linked MECP2 gene are the primary cause of the severe autism spectrum disorder RTT (Rett syndrome). Deletion of Mecp2 in mice recapitulates many of the overt neurological features seen in humans, and the delayed onset of symptoms is accompanied by deficits in neuronal morphology and synaptic physiology. Recent evidence suggests that reactivation of endogenous Mecp2 in young and adult mice can reverse aspects of RTT-like pathology. In the current perspective, we discuss these findings as well as other genetic, pharmacological and environmental interventions that attempt phenotypic rescue in RTT. We believe these studies provide valuable insights into the tractability of RTT and related conditions and are useful pointers for the development of future therapeutic strategies.
Insights
Reactivating the MECP2 gene in mice can reverse Rett syndrome (RTT) symptoms, offering hope for new therapeutic strategies for this severe neurological disorder.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Mutations in the X-linked MECP2 gene are the primary cause of Rett syndrome (RTT), a severe neurodevelopmental disorder.
- MECP2 deletion in mice models replicates key neurological features and synaptic deficits observed in human RTT patients.
- Delayed symptom onset in mouse models allows for investigation into potential therapeutic interventions.
Purpose of the Study:
- To review recent findings on reversing RTT-like pathology in mice.
- To discuss various intervention strategies for phenotypic rescue in RTT.
- To explore the potential for developing future therapeutic strategies for RTT and related conditions.
Main Methods:
- Review of existing literature on MECP2 gene function and RTT.
- Analysis of studies involving genetic, pharmacological, and environmental interventions in mouse models of RTT.
- Discussion of findings related to the reactivation of endogenous Mecp2.
Main Results:
- Reactivation of Mecp2 in young and adult mice has shown promise in reversing aspects of RTT-like pathology.
- Various intervention strategies are being explored for their efficacy in phenotypic rescue.
- Studies highlight the potential tractability of RTT and related conditions.
Conclusions:
- Reactivating Mecp2 offers a potential therapeutic avenue for RTT.
- Genetic, pharmacological, and environmental interventions show promise for RTT treatment.
- This research provides valuable insights for developing future therapies for RTT and related neurological disorders.
